Simultaneous multi-analyte urinary protein assay for bladder cancer detection

BMC Biotechnology

Volumn 14, Issue , 2014, Pages

  Rosser, Charles J ^a,b,c   Dai, Yunfeng ^d   Miyake, Makito ^a   Zhang, Ge ^a   Goodison, Steve ^a,b,e  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b Nonagen BioScience Corp   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Biomarkers; Bladder cancer; Protein; Q plex; Urine

Indexed keywords

ASSAYS; BIOMARKERS; MULTIPLEXING; PROTEINS;

BIOLOGIC SPECIMENS; BLADDER CANCERS; DIAGNOSTIC ACCURACY; METALLOPEPTIDASES; MULTIPLEX PROTEINS; Q-PLEX; URINE; VASCULAR ENDOTHELIAL GROWTH FACTOR-A;

DISEASES;

GELATINASE B; INTERLEUKIN 8; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898013583     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-14-24     Document Type: Article

References (27)

1. Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Med 2012, 10:87. 10.1186/1741-7015-10-87, 3425158, 22876833.
2. Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J, Stork-Sloots L, Generali D. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann SurgOncol 2012, 19:3257-3263.
3. Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST. Treatment choices based on oncotypeDx in the breast oncology care setting. J Cancer Epidemiol 2012, 2012:941495. 3425834, 22927848.
4. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, Lubman DM, Goodison S. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011, 17:3349-3359. 10.1158/1078-0432.CCR-10-3121, 3096687, 21459797.
5. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007, 6:2631-2639. 10.1021/pr0700807, 2668245, 17518487.
6. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012, 12:2149-2158.
7. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009, 2:444-453.
8. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S. Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol 2013, 190:2257-2262. 10.1016/j.juro.2013.06.011, 23764080.
9. Quansys Corp http://www.quansysbio.com, Quansys Corp.
10. Ekins RP. Ligand assays: from electrophoresis to miniaturized microarrays. Clin Chem 1998, 44:2015-2030.
11. Hatch W, Scalarone G. Comparison of colorimetric and chemiluminescent ELISAs for the detection of antibodies to blastomyces dermatitidis. J Med Biol Sci 2009, 3:19-25.
12. Samineni S, Parvataneni S, Kelly C, Gangur V, Karmaus W, Brooks K. Optimization, comparison, and application of colorimetric vs. chemiluminescence based indirect sandwich ELISA for measurement of human IL-23. J Immunoassay Immunochem 2006, 27:183-193. 10.1080/15321810600573051, 16711255.
13. Jantzie L, Tanay V, Todd K. Methods in immunochemistry. Handbook of neurochemistry and molecular neurobiology: Practical neurochemistry methods 2007, 193-218. New York, NY: Springer Science and Business Media, LLC, Lajtha A.
14. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ. Diagnostic potential of urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol 2012, 188(6):2377-2383. 10.1016/j.juro.2012.07.094, 23088986.
15. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 2012, 7:e37797. 10.1371/journal.pone.0037797, 3357344, 22629457.
16. Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, Rosser CJ. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol 2012, 12:12. 10.1186/1471-2490-12-12, 3404900, 22559832.
17. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urol 2012, 79:1185.e1-6. 3341520, 22386755.
18. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One 2012, 7(10):e47469. doi:10.1371/journal.pone.0047469. Epub 2012 Oct 19., 10.1371/journal.pone.0047469, 3477150, 23094052.
19. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. Aaps J 2007, 9:E156-E163. 10.1208/aapsj0902017, 2751404, 17614356.
20. Viswanathan CT, Bansal S, Booth D, DeStafano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 2007, 24:1962-1973. 10.1007/s11095-007-9291-7, 17458684.
21. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210. 10.1093/nar/30.1.207, 99122, 11752295.
22. Trune DR, Larrain BE, Hausman FA, Kempton JB, MacArthur CJ. Simultaneous measurement of multiple ear proteins with multiplex ELISA assays. Hear Res 2011, 275:1-7. 10.1016/j.heares.2010.11.009, 3087854, 21144888.
23. Zeng L, Liu J, Wang Y, Wang L, Weng S, Chen S, Yang GY. Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. Eur Neurol 2013, 69:68-75. 10.1159/000342896, 23154383.
24. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glaszious PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, STARD Group Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 2004, 21:4-10. 10.1093/fampra/cmh103, 14760036, STARD Group.
25. Bjerner J, Bormer OP, Nustad K. The war on heterophilic antibody interference. Clin Chem 2005, 51:9-11.
26. Motulsky H, Christopoulos H. Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting, 351 2004, 17. Oxford; New York: Oxford University Press.
27. Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biom J 2005, 47:458-472. 10.1002/bimj.200410135, 16161804.